-

01:11:21 AM

Latest ABT Stock Market News

ABT - Abbott Laboratories

09/15/21 12:46 PM

NYSE : ABT

dividends

Abbott Declares 391st Consecutive Quarterly Dividend

The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 45 cents per share.This marks the 391 st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2021, to

RHEA-AI

neutral

09/02/21 9:30 AM

NYSE : ABT

acquisition

Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC

Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots. Walk Vascular's

RHEA-AI

neutral

08/30/21 11:55 AM

NYSE : ABT

Late-Breaking Data Shows Abbott's Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke

Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company's Amplatzer™ Amulet Left Atrial Appendage (LAA) Occluder with the Watchman‡ device (Boston

RHEA-AI

neutral

08/16/21 8:00 AM

NYSE : ABT

Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke. The

RHEA-AI

neutral

08/03/21 9:00 AM

NYSE : ABT

Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart

Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software

RHEA-AI

very positive

08/02/21 9:00 AM

NYSE : ABT

Abbott's FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management

Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS application for use with compatible iPhones 1, providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous

RHEA-AI

neutral

07/29/21 9:00 AM

NYSE : ABT

New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations

A new study conducted by The Ohio State University and Abbott (NYSE: ABT) showed that half of the adults surveyed living with diabetes did not consume the daily recommended intake of protein, which is associated with lower diet quality, increased

RHEA-AI

neutral

07/22/21 7:15 AM

NYSE : ABT

Abbott Reports Second-Quarter 2021 Results

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2021.Second-quarter sales of $10.2 billion increased 39.5 percent on a reported basis and 35.0 percent on an organic basis, which excludes the impact of

RHEA-AI

neutral

06/30/21 9:00 AM

NYSE : ABT

fda approval

Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients

Abbott (NYSE: ABT) today announced its XIENCE family of stents has received U.S. Food and Drug Administration (FDA) approval for one-month (as short as 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S. In addition, XIENCE

RHEA-AI

very positive

06/25/21 11:30 AM

NYSE : ABT

Late-Breaking Data Demonstrate Abbott's FreeStyle® Libre System Supports Health Equity for Millions of Americans Living with Diabetes

Abbott (NYSE: ABT) today announced late-breaking data that showed FreeStyle Libre, the world's leading 7 continuous glucose monitoring (CGM) system, can support health equity through access to more affordable, life-changing technology for Americans

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next